Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
Titel:
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
Auteur:
Boudou-Rouquette, Pascaline Arrondeau, Jennifer Gervais, Claire Durand, Jean-Philippe Fabre, Elizabeth De Percin, Sixtine Villeminey, Clémentine Vaquin Piketty, Anne-Catherine Rassy, Nathalie Ulmann, Guillaume Damotte, Diane Mansuet-Lupo, Audrey Giraud, Frédérique Alifano, Marco Wislez, Marie Alexandre, Jérôme Jouinot, Anne Goldwasser, François